On July 31, 2025, Silexion Therapeutics Corp. entered into an inducement offer letter agreement with certain holders of 152,106 existing warrants. These warrants, originally issued in January 2025, were exercised for cash at a reduced price of $11.57 per share. In return, Silexion agreed to issue new warrants for 304,212 ordinary shares at an exercise price of $11.32 per share. The company anticipates gross proceeds of approximately $1.8 million from the transaction.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.